Gene Therapy Systems, Inc.

San Diego, CA 92121

SBIR Award Summary

Total Number of Awards 19
Total Value of Awards $6.15MM
First Award Date 04/01/99
Most Recent Award Date 09/20/13

Key Personnel

Last Name Name Awards Contact
Roth David Allan Roth 5
Felgner Philip Louis Felgner 8
Greener Alan Greener 6

19 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 09/20/13 - 03/19/14

DESCRIPTION (provided by applicant): Efficient delivery of DNA into E. coli remains a major limitation in the construction of high complex and representative gene libraries. The most efficient way developed to date is using electroporation - delivering an electric discharge to cell creating channels through which DNA can enter. We have created a...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-04-127
Budget: 04/26/10 - 08/31/11

DESCRIPTION (provided by applicant): This project will complete the identification and immunogenicity analyses of all proteins encoded by the Mycobacterium tuberculosis (Mtb) genome, yielding a pool of protective antigens that will immediately enter development as subunit vaccines for tuberculosis. In our prior SBIR Phase I grant (R43 AI053636-0...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-04-27
Budget: 09/01/08 - 08/31/10

DESCRIPTION (provided by applicant): This project will complete the identification and immunogenicity analyses of all proteins encoded by the Mycobacterium tuberculosis (Mtb) genome, yielding a pool of protective antigens that will immediately enter development as subunit vaccines for tuberculosis. In our prior SBIR Phase I grant (R43 AI053636-0...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-04-27
Budget: 09/01/07 - 08/31/08

DESCRIPTION (provided by applicant): This project will complete the identification and immunogenicity analyses of all proteins encoded by the Mycobacterium tuberculosis (Mtb) genome, yielding a pool of protective antigens that will immediately enter development as subunit vaccines for tuberculosis. In our prior SBIR Phase I grant (R43 AI053636-0...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 05/01/07 - 10/31/08

DESCRIPTION (provided by applicant): For most applications, recombinant proteins must be purified in soluble form; however, when expressed in E. coli, many proteins fold aberrantly and become an insoluble aggregate in the cell. We propose to create a genetic method to allow scientists using E. coli for recombinant protein expression to immediate...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-04-27
Budget: 09/30/06 - 08/31/07

DESCRIPTION (provided by applicant): This project will complete the identification and immunogenicity analyses of all proteins encoded by the Mycobacterium tuberculosis (Mtb) genome, yielding a pool of protective antigens that will immediately enter development as subunit vaccines for tuberculosis. In our prior SBIR Phase I grant (R43 AI053636-0...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-00-126
Budget: 07/01/04 - 06/30/07

DESCRIPTION: (Provided by Applicant) DNA vaccines offer an attractive alternative to create effective vaccines that are inexpensive to manufacture, and can be widely distributed. One of the most difficult tasks in developing a DNA vaccine is the identification of the antigen that will stimulate the most effective immune response against the path...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-00-126
Budget: 07/01/03 - 06/30/04

DESCRIPTION: (Provided by Applicant) DNA vaccines offer an attractive alternative to create effective vaccines that are inexpensive to manufacture, and can be widely distributed. One of the most difficult tasks in developing a DNA vaccine is the identification of the antigen that will stimulate the most effective immune response against the path...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-AI-02-05
Budget: 09/30/02 - 09/29/04

DESCRIPTION (provided by applicant): A technology developed by Gene Therapy Systems Inc. under a previously funded Phase I SBIR grant will be applied to producing the complete proteome from vaccinia virus and the proteome will be applied to the general problem of identifying potent vaccine antigens affective against smallpox. The technology ca...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-00-126
Budget: 09/15/02 - 03/14/05

DESCRIPTION (provided by applicant): One of the most difficult tasks in developing a subunit vaccine is the identification of the antigens that will stimulate the most effective immune response against the pathogen, particularly when the genome of the infectious organism is large. A technology developed by Gene Therapy Systems Inc. under a prev...

Load More